Abbott To Buy Solvay's Pharma Unit For $6.6B Cash

Law360, New York (September 28, 2009, 3:09 PM EDT) -- Abbott Laboratories plans to buy the pharmaceutical business of Belgium's Solvay Group for $6.6 billion in cash in a move to expand its presence in key emerging markets and diversify its drug portfolio.

The Illinois-based drugmaker said Monday that the acquisition would add more than $3 billion in annual sales and position it in high-growth markets in Eastern Europe and Asia. It will also add about $500 million a year for pharmaceutical research and development investment, the company said.

“In anticipation of future market needs, we...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.